NanoViricides Inc
NNVCHealthcare·Biotechnology·USA·Nano·AMEX·Nov 12 • 3:59 PM ET
1.35-0.03 (-2.17%)
2026-11-13 13:36 CET
Market cap
$34.46M
Revenue, TTM
0.00 USD m
Net income, TTM
-8.22 USD m
Free cash flow, TTM
-7.78 USD m
EPS diluted, TTM
-0.41
Price
NNVC against its 20, 50 and 200-day averagesPatternshover a marker to name it
30.1% under the 52-week high of 1.93 on 28 May 2026. 52-week low 0.85 on 5 Feb 2026. Last 15 sessions, 19.0% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 34
CANSLIM 1 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 5 of 6 — fails: 52-Week High/Low: 0-10% below High
Minervini 2 of 4 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 2 of 5 — fails: Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Return on Equity: Over +15% — not on the tape: EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: Average Volume: Over 500K; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; Average Volume: Over 500K
Profile
NNVC52-week range, 46% of the way up
0.851.93
NanoViricides, Inc. is a clinical stage company, which engages in the development of nano-biopharmaceutical drugs against viruses. It focuses on anti-viral therapeutics through internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.
| Employees | 7 |
|---|---|
| IPO | Aug 12, 2004 |
| Beta | 1.83 |
| ATR, 14d | 0.10 |
| Rel volume | 0.00 |
| Short float | 3.26% |
| Insider own | 2.49% |
| Inst own | 9.33% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $34.46M |
| Enterprise Value | 31.67M |
| Income | -8.22M |
| Sales | 0.00M |
| Book / share | 0.38 |
| Cash / share | 0.11 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 7 |
| IPO | Aug 12, 2004 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 3.58 |
| Price / cash | 12.35 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 2.66 |
| Current Ratio | 2.66 |
| Debt / equity | 0.00 |
| Long-term debt / equity | 0.00 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.41 |
|---|---|
| Earnings next year | - |
| Earnings next quarter | -0.10 |
| Earnings this year | -6.98% |
| Earnings next year | - |
| Earnings growth, 5 years | - |
| Past earnings growth | 18.01% 12.84% |
| Past sales growth | - - |
| Earnings vs last year | 35.47% |
| Sales vs last year | - |
| Earnings vs last quarter | 21.51% |
| Sales vs last quarter | - |
| Earnings | Sep 02 |
| Surprise | -10.00% - |
Ownership
| Insiders own | 2.49% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 9.33% |
| Institution trades | 1.64% |
| Return on assets | -87.91% |
| Return on equity | -101.46% |
| Return on capital | -94.65% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -2.67% |
| 50-day average | 1.17% |
| 200-day average | 3.83% |
Technical
| Shares out | 25.52M |
|---|---|
| Shares floating | 24.89M |
| Short / float | 3.26% |
| Short ratio | 2.22 |
| Short interest | 0.81M |
| 52-week high | 1.93 -30.1% |
| 52-week low | 0.85 +58.8% |
| Volatility | 6.64% 7.47% |
| Average range | 0.10 |
| Strength index | 48.67 |
| Market sensitivity | 1.83 |
| Relative volume | 0.00 |
| Avg Volume | 365.46K |
| Volume | 0 |
Performance
| Perf Week | 4.65% |
|---|---|
| Perf Month | 3.05% |
| Perf Quarter | -2.17% |
| Perf Half Y | -22.41% |
| Perf YTD | 19.47% |
| Perf Year | -10.00% |
| Perf 3Y | 27.36% |
| Perf 5Y | -71.09% |
| Perf 10Y | -95.11% |
| Recommendation | 1.00 |
| Target Price | 6.00 |
| Prev Close | 1.35 |
| Price | 1.35 |
| Change % | 0.00% |
Analyst ratings
latest 2 of 2| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Dec 16, 2025 | Initiated | Alliance Global Partners | Buy | ||
| Feb 11, 2015 | Initiated | Midtown Partners | Strong Buy | $5.30 | +292.6% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| COCP | Cocrystal Pharma Inc | 19.07M |
| ALGS | Aligos Therapeutics Inc | 13.96M |
| ENTA | Enanta Pharmaceuticals Inc | 326.20M |
| TRAW | Traws Pharma Inc | 4.15M |
| AVIR | Atea Pharmaceuticals Inc | 338.08M |
| IVVD | Invivyd Inc | 170.96M |
| SIGA | SIGA Technologies Inc | 207.66M |
| VIR | Vir Biotechnology Inc | 1.75B |
| TNXP | Tonix Pharmaceuticals Holding Corp | 62.76M |
| EBS | Emergent Biosolutions Inc | 300.27M |
Held by
AUMNews
latest 14 of 200- As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides (ACCESSWIRE) +7.35%
- NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials (ACCESSWIRE) +13.85%
- Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides (ACCESSWIRE)
- NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 (ACCESSWIRE)
- NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives (ACCESSWIRE) +13.28%
- NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials (ACCESSWIRE) -13.33%
- NanoViricides: Fiscal Q4 Earnings Snapshot (Associated Press)
- Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides (ACCESSWIRE)
- Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides (ACCESSWIRE)
- Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in ?DR Congo with 48% Crude Fatality Rate, Says NanoViricides (ACCESSWIRE)
- Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo (ACCESSWIRE)
- While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles (ACCESSWIRE)
- The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon (ACCESSWIRE)
- NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak (ACCESSWIRE)
Quarterly earnings
2026Q4 EPS -0.110 missed -0.100, from -0.120 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q4ended 2026-06-30 | 2026-09-02 12:00 | -0.110 | -0.100 | -0.100 | 0.00 | 0.00 | EPS +10.0% · sales - | vs 2025Q4, year-ago quarter · EPS -8.3% · sales - | 2 EPS · 1 sales | Open +2.48% vs SPY +0.09%. Close -3.31% vs SPY +0.44% |
| 2026Q3ended 2026-03-31 | 2026-05-19 12:00 | -0.095 | - | -0.092 | 0.00 | - | EPS - · sales - | vs 2025Q3, year-ago quarter · EPS - · sales - | - | Open +2.65% vs SPY -0.52%. Close +5.30% vs SPY -0.67% |
| 2026Q2ended 2025-12-31 | 2026-02-11 12:00 | -0.110 | -0.110 | -0.112 | 0.00 | 0.00 | EPS 0.0% · sales - | vs 2025Q2, year-ago quarter · EPS - · sales - | 2 EPS · 1 sales | Open +0.99% vs SPY +0.62%. Close 0.00% vs SPY -0.02% |
| 2026Q1ended 2025-09-30 | 2025-12-03 12:00 | -0.135 | -0.180 | -0.105 | 0.00 | 0.00 | EPS -25.0% · sales - | vs 2025Q1, year-ago quarter · EPS - · sales - | 1 | Open 0.00% vs SPY -0.14%. Close +1.83% vs SPY +0.35% |
| 2025Q4ended 2025-06-30 | 2025-09-03 12:00 | -0.120 | - | -0.127 | 0.00 | - | EPS - · sales - | vs 2024Q4, year-ago quarter · EPS - · sales - | - | Open 0.00% vs SPY +0.37%. Close +2.14% vs SPY +0.54% |
| 2024Q3ended 2024-03-31 | 2024-05-14 12:00 | -0.510 | -0.150 | -0.157 | 0.00 | - | EPS +240.0% · sales - | - | 1 | Open +8.79% vs SPY +0.04%. Close +24.18% vs SPY +0.46% |
| 2024Q2ended 2023-12-31 | 2024-02-16 16:30 | -0.180 | -0.190 | -0.180 | 0.00 | - | EPS -5.3% · sales - | vs 2023Q2, year-ago quarter · EPS +20.0% · sales - | 1 | Open +0.81% vs SPY -0.36%. Close +0.81% vs SPY -0.55% |
| 2023Q2ended 2022-12-31 | 2023-05-13 | -0.150 | - | -0.150 | - | - | EPS - · sales - | vs 2022Q2, year-ago quarter · EPS -11.8% · sales - | 1 | Open -2.46% vs SPY +0.02%. Close -8.20% vs SPY +0.21% |
| 2023Q1ended 2022-09-30 | 2023-01-28 | -0.140 | - | -0.136 | - | - | EPS - · sales - | - | 1 | Open +1.37% vs SPY -0.48%. Close -1.38% vs SPY -1.03% |
| 2022Q4ended 2022-06-30 | 2022-10-14 | -0.150 | - | -0.154 | - | - | EPS - · sales - | - | 1 | Open +2.34% vs SPY +0.70%. Close +2.34% vs SPY -2.28% |
| 2022Q3ended 2022-03-31 | 2022-05-17 | -0.160 | -0.160 | -0.155 | - | - | EPS 0.0% · sales - | - | 1 | Open +0.69% vs SPY +1.61%. Close +2.76% vs SPY +2.06% |
| 2022Q2ended 2021-12-31 | 2022-04-13 | -0.170 | - | -0.167 | - | - | EPS - · sales - | - | - | Open -1.63% vs SPY -0.06%. Close +4.89% vs SPY +1.15% |
| 2024Q4ended 2024-06-30 | - | - | -0.310 | -0.193 | - | - | EPS - · sales - | - | 1 | - |
| 2025Q1ended 2024-09-30 | - | - | -0.170 | -0.228 | - | - | EPS - · sales - | - | 1 | - |
| 2025Q2ended 2024-12-31 | - | - | -0.180 | -0.139 | - | - | EPS - · sales - | vs 2024Q2, year-ago quarter · EPS - · sales - | 1 | - |
| 2025Q3ended 2025-03-31 | - | - | -0.190 | -0.138 | - | - | EPS - · sales - | vs 2024Q3, year-ago quarter · EPS - · sales - | 1 | - |
Annual earnings
2026FY EPS -0.430 missed -0.415, from -0.630 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2029FYestimate | - | 0.950 | - | - | 133.5 | 1.42 |
| 2028FYestimate | - | 0.500 | - | - | 76.50 | 2.70 |
| 2027FYestimate | - | -0.460 | - | - | 0.00 | - |
| 2026FY | -0.430 | -0.415 | -0.430 | 0.00 | 0.00 | - |
| 2025FY | -0.630 | - | -0.626 | 0.00 | - | - |
| 2023FY | -0.430 | -0.430 | -0.739 | - | - | - |
| 2022FY | -0.700 | - | -0.703 | - | - | - |
| 2020FY | -2.390 | - | -2.394 | 0.00 | - | - |
| 2014FY | -5.600 | -4.600 | -5.600 | - | 0.00 | - |
| 2011FY | -3.500 | -3.500 | -3.500 | - | 0.00 | - |
Quarterly results
2026Q4 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2027FY E -0.46 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2027FY | E | per share | 2026-09-02 | -0.46 | +13.6% |
| 2027Q1 | E | per share | 2026-09-02 | -0.10 | +5.3% |
| 2027FY | R | per share | 2026-09-02 | -0.46 | 0.0% |
| 2027Q1 | R | per share | 2026-09-02 | -0.10 | 0.0% |
| 2027FY | S | per share | 2026-09-02 | 0.00 | - |
| 2027Q1 | S | per share | 2026-09-02 | 0.00 | - |
| 2026FY | E | per share | 2026-07-07 | -0.42 | 0.0% |
| 2026Q4 | E | per share | 2026-07-07 | -0.10 | 0.0% |
| 2026FY | R | per share | 2026-07-02 | -0.43 | +19.4% |
| 2026Q4 | R | per share | 2026-07-02 | -0.11 | -42.1% |
| 2026Q4 | S | per share | 2026-07-02 | 0.00 | - |
| 2026Q3 | E | per share | 2026-05-19 | -0.09 | +12.5% |
| 2026Q2 | E | per share | 2026-02-14 | -0.08 | -27.3% |
| 2026Q3 | R | per share | 2026-02-11 | -0.13 | 0.0% |
| 2026Q3 | S | per share | 2026-02-11 | 0.00 | - |
| 2026Q2 | R | per share | 2025-12-03 | -0.14 | 0.0% |
| 2026Q2 | S | per share | 2025-12-03 | 0.00 | - |
| 2026Q1 | E | per share | 2025-11-06 | -0.18 | - |
| 2026Q1 | R | per share | 2025-11-06 | -0.18 | - |
| 2026FY | S | per share | 2025-11-06 | 0.00 | - |
| 2026Q1 | S | per share | 2025-11-06 | 0.00 | - |
| 2024Q4 | E | per share | 2024-08-13 | -0.31 | 0.0% |
| 2024Q3 | E | per share | 2024-05-06 | -0.15 | -21.1% |
| 2023FY | E | per share | 2023-08-29 | -0.43 | 0.0% |
Estimate history
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -2.6 | -2.347 | -2.394 | -0.809 | -0.703 | -0.739 | -0.699 | -0.626 | -0.407 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 3 | 4 | 9 | 12 | 12 | 12 | 13 | 17 | 23 |
| Metric | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.193 | -0.228 | -0.139 | -0.138 | -0.127 | -0.105 | -0.112 | -0.092 | -0.1 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 13 | 14 | 16 | 16 | 17 | 18 | 22 | 22 | 23 |
Income statement, annual
| Metric | TTM | 2026FY6/30/2026 | 2025FY6/30/2025 | 2024FY6/30/2024 | 2023FY6/30/2023 | 2022FY6/30/2022 | 2021FY6/30/2021 | 2020FY6/30/2020 | 2019FY6/30/2019 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.53 | 0.53-28.4% | 0.74-2.6% | 0.76+1.3% | 0.75+4.2% | 0.72+2.9% | 0.700.0% | 0.700.0% | 0.70 |
| Gross Profit | -0.53 | -0.53 | -0.74 | -0.76 | -0.75 | -0.72 | -0.70 | -0.70 | -0.70 |
| Selling, General and Administrative Excl. Other | 7.78 | 7.78-12.1% | 8.85+14.0% | 7.76-5.4% | 8.20+11.0% | 7.39-8.1% | 8.04+10.1% | 7.30-8.3% | 7.96 |
| Research and Development | 4.71 | 4.71-15.1% | 5.55+2.0% | 5.44-14.9% | 6.39+10.6% | 5.78-5.4% | 6.11+30.0% | 4.70-20.6% | 5.92 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -8.31 | -8.31 | -9.59 | -8.52 | -8.94 | -8.11 | -8.74 | -8.00 | -8.66 |
| Interest Expense | 0.00 | 0.00 | 0.00-100.0% | 0.05 | 0.00-100.0% | 0.01-88.9% | 0.090.0% | 0.09 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 5.99 | -0.18 |
| Net Income Before Taxes | -8.22 | -8.22 | -9.47 | -8.29 | -8.59 | -8.11 | -8.82 | -13.45 | -8.42 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -8.22 | -8.22 | -9.47 | -8.29 | -8.59 | -8.11 | -8.82 | -13.45 | -8.42 |
| Net Income From Continuing Operations | -8.22 | -8.22 | -9.47 | -8.29 | -8.59 | -8.11 | -8.82 | -13.45 | -8.42 |
| Net Income | -8.22 | -8.22 | -9.47 | -8.29 | -8.59 | -8.11 | -8.82 | -13.45 | -8.42 |
| EPS (Recurring) per share | -0.37 | -0.41 | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -1.65 | -2.38 |
| EPS (Basic, Before Extraordinaries) per share | -0.41 | -0.41 | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -2.39 | -2.35 |
| EPS (Diluted) per share | -0.41 | -0.41 | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -2.39 | -2.35 |
| EBITDA | -7.78 | -7.78 | -8.85 | -7.76 | -8.20 | -7.39 | -8.04 | -7.30 | -7.96 |
| Non-Operating Income (Expense) | 0.09 | 0.09-25.0% | 0.12-55.6% | 0.27-25.0% | 0.36+3500.0% | 0.010.0% | 0.01-98.4% | 0.63+950.0% | 0.06 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.05 | 0.05-16.7% | 0.06+20.0% | 0.05-16.7% | 0.06-57.1% | 0.14-41.7% | 0.24-7.7% | 0.26+2500.0% | 0.01 |
| Shares Outstanding million shares | 23.01 | 23.01+38.5% | 16.61+26.4% | 13.14+12.3% | 11.70+0.9% | 11.59+0.6% | 11.52+26.9% | 9.08+136.5% | 3.84 |
| Market Capitalization | 34.46 | 34.46+53.2% | 22.50+10.7% | 20.32+51.4% | 13.42-38.2% | 21.72-59.3% | 53.38-21.3% | 67.87+268.5% | 18.42 |
Income statement, quarterly
| Metric | 2026Q46/30/2026 | 2026Q33/31/2026 | 2026Q212/31/2025 | 2026Q19/30/2025 | 2025Q46/30/2025 | 2025Q33/31/2025 | 2025Q212/31/2024 | 2025Q19/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.13-18.8% | 0.13-31.6% | 0.13-35.0% | 0.13-35.0% | 0.16-15.8% | 0.190.0% | 0.20+5.3% | 0.20+5.3% |
| Gross Profit | -0.13 | -0.13 | -0.13 | -0.13 | -0.16 | -0.19 | -0.20 | -0.20 |
| Selling, General and Administrative Excl. Other | 2.12+8.7% | 1.90-7.8% | 2.10+12.9% | 1.66-44.1% | 1.95-11.4% | 2.06+19.8% | 1.86-7.0% | 2.97+61.4% |
| Research and Development | 1.31+11.0% | 1.29+0.8% | 1.12-3.4% | 0.99-48.7% | 1.180.0% | 1.28+5.8% | 1.16-26.1% | 1.93+31.3% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.25 | -2.03 | -2.23 | -1.80 | -2.12 | -2.25 | -2.06 | -3.17 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -2.22 | -1.99 | -2.22 | -1.79 | -2.10 | -2.22 | -2.03 | -3.13 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.22 | -1.99 | -2.22 | -1.79 | -2.10 | -2.22 | -2.03 | -3.13 |
| Net Income From Continuing Operations | -2.22 | -1.99 | -2.22 | -1.79 | -2.10 | -2.22 | -2.03 | -3.13 |
| Net Income | -2.22 | -1.99 | -2.22 | -1.79 | -2.10 | -2.22 | -2.03 | -3.13 |
| EPS (Recurring) per share | -0.10 | -0.09 | -0.11 | -0.10 | -0.13 | -0.14 | -0.14 | -0.23 |
| EPS (Basic, Before Extraordinaries) per share | -0.10 | -0.09 | -0.11 | -0.10 | -0.13 | -0.14 | -0.14 | -0.23 |
| EPS (Diluted) per share | -0.10 | -0.09 | -0.11 | -0.10 | -0.13 | -0.14 | -0.14 | -0.23 |
| EBITDA | -2.12 | -1.90 | -2.10 | -1.66 | -1.95 | -2.06 | -1.86 | -2.97 |
| Non-Operating Income (Expense) | 0.020.0% | 0.04+33.3% | 0.01-66.7% | 0.01-75.0% | 0.02-50.0% | 0.03-40.0% | 0.03-62.5% | 0.04-60.0% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.01-50.0% | 0.01-83.3% | 0.010.0% | 0.010.0% | 0.02+100.0% | 0.06+500.0% | 0.010.0% | 0.010.0% |
| Shares Outstanding million shares | 23.01+38.5% | 21.65+34.7% | 21.60+38.1% | 17.56+24.9% | 16.61+26.4% | 16.07+36.1% | 15.64+32.8% | 14.06+19.7% |
| Market Capitalization | 34.46+53.2% | 19.70+7.7% | 24.37+18.8% | 22.98+29.7% | 22.50+10.7% | 18.30+34.0% | 20.52+71.3% | 17.72+13.0% |
Balance sheet, annual
| Metric | 2026FY6/30/2026 | 2025FY6/30/2025 | 2024FY6/30/2024 | 2023FY6/30/2023 | 2022FY6/30/2022 | 2021FY6/30/2021 | 2020FY6/30/2020 | 2019FY6/30/2019 | 2018FY6/30/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 2.79+78.8% | 1.56-67.5% | 4.80-41.1% | 8.15-42.1% | 14.07-31.4% | 20.52+49.7% | 13.71+435.5% | 2.56-63.8% | 7.08 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.37+236.4% | 0.11-35.3% | 0.17-43.3% | 0.30-14.3% | 0.35+12.9% | 0.31+10.7% | 0.28+3.7% | 0.27+12.5% | 0.24 |
| Total Current Assets | 3.16+89.2% | 1.67-66.4% | 4.97-41.2% | 8.45-41.4% | 14.42-30.7% | 20.82+48.8% | 13.99+394.3% | 2.83-61.3% | 7.32 |
| Net Property, Plant & Equipment | 6.40-6.3% | 6.83-9.1% | 7.51-7.4% | 8.11-6.7% | 8.69-4.3% | 9.08-4.8% | 9.54-6.7% | 10.23-5.6% | 10.84 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.31-3.1% | 0.32-3.0% | 0.330.0% | 0.33-2.9% | 0.34-2.9% | 0.35-2.8% | 0.36-2.7% | 0.370.0% | 0.37 |
| Other Assets | 0.00 | 0.00-100.0% | 0.010.0% | 0.01-75.0% | 0.04 | 0.00-100.0% | 0.030.0% | 0.03+200.0% | 0.01 |
| Total Assets | 9.87+11.9% | 8.82-31.2% | 12.82-24.1% | 16.90-28.1% | 23.49-22.4% | 30.26+26.6% | 23.91+77.8% | 13.45-27.5% | 18.55 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.09-10.0% | 0.10-91.2% | 1.14 | 0.00 | 0.00 |
| Accounts Payable | 1.15-10.2% | 1.28+16.4% | 1.10+182.1% | 0.39+44.4% | 0.27+17.4% | 0.23-75.5% | 0.94-16.8% | 1.13+242.4% | 0.33 |
| Other Current Liabilities | 0.04+33.3% | 0.03-88.5% | 0.26+85.7% | 0.14+180.0% | 0.05+150.0% | 0.02-71.4% | 0.07-95.9% | 1.71+210.9% | 0.55 |
| Total Current Liabilities | 1.19-9.2% | 1.31-3.7% | 1.36+156.6% | 0.53+29.3% | 0.41+17.1% | 0.35-83.8% | 2.16-24.2% | 2.85+223.9% | 0.88 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00-100.0% | 1.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.19-9.2% | 1.31-3.7% | 1.36-33.0% | 2.03+395.1% | 0.41+17.1% | 0.35-83.8% | 2.16-24.2% | 2.85+223.9% | 0.88 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 9E-060.0% | 9E-060.0% | 9E-06+80.0% | 5E-06 | 0.00 | 0.00 | 0.00-100.0% | 0.01 | 0.00 |
| Common Equity | 8.68+15.4% | 7.52-34.4% | 11.46-22.9% | 14.87-35.6% | 23.08-22.8% | 29.91+37.5% | 21.76+105.3% | 10.60-40.0% | 17.66 |
| Total Shareholders Equity | 8.68+15.4% | 7.52-34.4% | 11.46-22.9% | 14.87-35.6% | 23.08-22.8% | 29.91+37.5% | 21.76+105.3% | 10.60-40.0% | 17.66 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 8.68+15.4% | 7.52-34.4% | 11.46-22.9% | 14.87-35.6% | 23.08-22.8% | 29.91+37.5% | 21.76+105.3% | 10.60-40.0% | 17.66 |
| Total Liabilities & Stockholders Equity | 9.87+11.9% | 8.82-31.2% | 12.82-24.1% | 16.90-28.1% | 23.49-22.4% | 30.26+26.6% | 23.91+77.8% | 13.45-27.5% | 18.55 |
| Book Value Per Share per share | 0.38-15.6% | 0.45-48.3% | 0.87-31.5% | 1.27-36.2% | 1.99-23.5% | 2.60+8.3% | 2.40-13.0% | 2.76-46.0% | 5.11 |
| Tangible Book Value Per Share per share | 0.36-16.3% | 0.43-49.4% | 0.85-31.5% | 1.24-36.7% | 1.96-23.7% | 2.57+8.9% | 2.36-11.3% | 2.66-46.8% | 5.00 |
| Full-Time Employees people | 70.0% | 70.0% | 70.0% | 7-58.8% | 170.0% | 170.0% | 170.0% | 17-43.3% | 30 |
| Price to Book Ratio ratio | 3.58 | 2.55 | 1.91 | 0.91 | 0.94 | 1.79 | 3.12 | 1.45 | 1.59 |
| Return on Assets % | -87.91 | -87.47 | -55.81 | -42.52 | -30.16 | -32.57 | -71.98 | -52.66 | -37.60 |
| Return on Equity % | -101.46 | -99.75 | -63.00 | -45.27 | -30.60 | -34.15 | -83.11 | -59.61 | -45.09 |
| Return on Invested Capital % | -94.65 | -125.93 | -72.35 | -57.77 | -35.12 | -29.49 | -61.80 | -79.47 | -48.48 |
| Quick Ratio ratio | 2.66 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 |
| Current Ratio ratio | 2.66 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 |
Cash flow, annual
| Metric | TTM | 2026FY6/30/2026 | 2025FY6/30/2025 | 2024FY6/30/2024 | 2023FY6/30/2023 | 2022FY6/30/2022 | 2021FY6/30/2021 | 2020FY6/30/2020 | 2019FY6/30/2019 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -8.22 | -8.22 | -9.47 | -8.29 | -8.59 | -8.11 | -8.82 | -13.45 | -8.42 |
| Depreciation | 0.53 | 0.53-28.4% | 0.74-2.6% | 0.76+1.3% | 0.75+4.2% | 0.72+2.9% | 0.700.0% | 0.700.0% | 0.70 |
| Other Funds (Non Cash) | 0.37 | 0.37+68.2% | 0.220.0% | 0.22-40.5% | 0.37-71.1% | 1.28+190.9% | 0.44-92.6% | 5.95+1552.8% | 0.36 |
| Funds from Operations | -7.33 | -7.33 | -8.50 | -7.31 | -7.47 | -6.11 | -7.67 | -6.80 | -7.37 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.37 | -0.37-1950.0% | 0.02-98.0% | 1.00-44.4% | 1.80+757.1% | 0.21 | -0.54-550.0% | 0.12-78.9% | 0.57 |
| Cash from Operating Activities | -7.70 | -7.70 | -8.48 | -6.32 | -5.67 | -5.89 | -8.21 | -6.68 | -6.80 |
| Capital Expenditures | -0.08 | -0.08 | -0.06 | -0.16 | -0.15 | -0.32 | -0.24 | -0.01 | -0.07 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.08 | -0.08 | -0.06 | -0.16 | -0.15 | -0.32 | -0.24 | -0.01 | -0.07 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 9.02 | 9.02+70.2% | 5.30+69.9% | 3.12 | 0.00 | 0.00-100.0% | 16.56-0.7% | 16.68+609.8% | 2.35 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 9.02 | 9.02+70.2% | 5.30+69.9% | 3.12 | 0.00 | 0.00-100.0% | 16.56-0.7% | 16.68+609.8% | 2.35 |
| Proceedsfrom Stock Options | 9.02 | 9.02+70.2% | 5.30+69.9% | 3.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 | -0.23 | -1.30-212.1% | 1.16 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 9.02 | 9.02+70.2% | 5.30+69.9% | 3.12 | -0.09 | -0.23-101.5% | 15.26-14.5% | 17.84+659.1% | 2.35 |
| Net Change in Cash | 1.24 | 1.24 | -3.24 | -3.35 | -5.92 | -6.45-194.7% | 6.81-38.9% | 11.15 | -4.53 |
| Free Cash Flow | -7.78 | -7.78 | -8.54 | -6.47 | -5.82 | -6.22 | -8.45 | -6.69 | -6.88 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q46/30/2026 | 2026Q33/31/2026 | 2026Q212/31/2025 | 2026Q19/30/2025 | 2025Q46/30/2025 | 2025Q33/31/2025 | 2025Q212/31/2024 | 2025Q19/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 2.79+78.8% | 3.21+26.4% | 5.15+30.1% | 1.13-70.8% | 1.56-67.5% | 2.54-22.1% | 3.96-24.6% | 3.87-44.5% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.37+236.4% | 0.16-11.1% | 0.15+36.4% | 0.13-27.8% | 0.11-35.3% | 0.18-30.8% | 0.11+57.1% | 0.18+5.9% |
| Total Current Assets | 3.16+89.2% | 3.38+23.8% | 5.30+30.2% | 1.25-69.1% | 1.67-66.4% | 2.73-22.4% | 4.07-23.5% | 4.04-43.4% |
| Net Property, Plant & Equipment | 6.40-6.3% | 6.53-6.4% | 6.66-7.1% | 6.79-7.9% | 6.83-9.1% | 6.98-8.2% | 7.17-7.5% | 7.37-7.1% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.31-3.1% | 0.31-3.1% | 0.31-3.1% | 0.31-3.1% | 0.32-3.0% | 0.32-3.0% | 0.32-3.0% | 0.32-3.0% |
| Other Assets | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.010.0% | 0.010.0% |
| Total Assets | 9.87+11.9% | 10.22+1.9% | 12.27+6.1% | 8.36-28.8% | 8.82-31.2% | 10.03-12.5% | 11.57-13.7% | 11.74-23.9% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 1.15-10.2% | 1.04-11.1% | 1.15+2.7% | 1.16-14.1% | 1.28+16.4% | 1.17+112.7% | 1.12+45.5% | 1.35+121.3% |
| Other Current Liabilities | 0.04+33.3% | 0.030.0% | 0.05-28.6% | 0.03-89.3% | 0.03-88.5% | 0.03-88.5% | 0.07-61.1% | 0.28-17.6% |
| Total Current Liabilities | 1.19-9.2% | 1.07-10.8% | 1.20+1.7% | 1.18-27.6% | 1.31-3.7% | 1.20+48.1% | 1.18+24.2% | 1.63+71.6% |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Total Liabilities | 1.19-9.2% | 1.07-10.8% | 1.20+1.7% | 1.18-27.6% | 1.31-3.7% | 1.20+48.1% | 1.18+24.2% | 1.63-33.5% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 9E-060.0% | 9E-060.0% | 9E-060.0% | 9E-060.0% | 9E-060.0% | 9E-060.0% | 9E-060.0% | 9E-06+80.0% |
| Common Equity | 8.68+15.4% | 9.15+3.6% | 11.07+6.5% | 7.17-29.1% | 7.52-34.4% | 8.83-17.1% | 10.39-16.5% | 10.11-22.1% |
| Total Shareholders Equity | 8.68+15.4% | 9.15+3.6% | 11.07+6.5% | 7.17-29.1% | 7.52-34.4% | 8.83-17.1% | 10.39-16.5% | 10.11-22.1% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 8.68+15.4% | 9.15+3.6% | 11.07+6.5% | 7.17-29.1% | 7.52-34.4% | 8.83-17.1% | 10.39-16.5% | 10.11-22.1% |
| Total Liabilities & Stockholders Equity | 9.87+11.9% | 10.22+1.9% | 12.27+6.1% | 8.36-28.8% | 8.82-31.2% | 10.03-12.5% | 11.57-13.7% | 11.74-23.9% |
| Book Value Per Share per share | 0.38-15.6% | 0.42-23.6% | 0.51-22.7% | 0.41-43.1% | 0.45-48.3% | 0.55-38.9% | 0.66-37.7% | 0.72-34.5% |
| Tangible Book Value Per Share per share | 0.36-16.3% | 0.41-22.6% | 0.50-21.9% | 0.39-44.3% | 0.43-49.4% | 0.53-39.1% | 0.64-37.9% | 0.70-35.2% |
| Full-Time Employees people | 70.0% | - | - | - | 70.0% | - | - | - |
| Price to Book Ratio ratio | 3.58 | 2.16 | 2.77 | 3.16 | 2.55 | 1.76 | 1.99 | 1.72 |
| Return on Assets % | -87.91 | -79.91 | -69.79 | -80.86 | -87.47 | -90.50 | -75.00 | -69.61 |
| Return on Equity % | -101.46 | -89.97 | -77.53 | -94.03 | -99.75 | -99.84 | -82.01 | -81.92 |
| Return on Invested Capital % | -25.61 | -21.73 | -20.06 | -24.88 | -27.88 | -25.10 | -19.52 | -30.93 |
| Quick Ratio ratio | 2.66 | 3.17 | 4.43 | 1.06 | 1.28 | 2.27 | 3.44 | 2.48 |
| Current Ratio ratio | 2.66 | 3.17 | 4.43 | 1.06 | 1.28 | 2.27 | 3.44 | 2.48 |
Cash flow, quarterly
| Metric | 2026Q46/30/2026 | 2026Q33/31/2026 | 2026Q212/31/2025 | 2026Q19/30/2025 | 2025Q46/30/2025 | 2025Q33/31/2025 | 2025Q212/31/2024 | 2025Q19/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -2.22 | -1.99 | -2.22 | -1.79 | -2.10 | -2.22 | -2.03 | -3.13 |
| Depreciation | 0.13-18.8% | 0.13-31.6% | 0.13-35.0% | 0.13-35.0% | 0.16-15.8% | 0.190.0% | 0.20+5.3% | 0.20+5.3% |
| Other Funds (Non Cash) | 0.050.0% | 0.07+16.7% | 0.20+300.0% | 0.05-16.7% | 0.050.0% | 0.06+20.0% | 0.050.0% | 0.06-14.3% |
| Funds from Operations | -2.04 | -1.79 | -1.89 | -1.60 | -1.88 | -1.97 | -1.78 | -2.87 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.08-144.4% | -0.14 | -0.16 | 0.01-96.4% | 0.18-71.9% | -0.02 | -0.41-356.3% | 0.28-48.1% |
| Cash from Operating Activities | -2.12 | -1.93 | -2.05 | -1.59 | -1.70 | -1.99 | -2.19 | -2.59 |
| Capital Expenditures | -1E-06 | 0.00 | 1E-06 | -0.08 | -0.01 | 0.00 | 0.00 | -0.05 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -1E-06 | 0.00 | 1E-06 | -0.08 | -0.01 | 0.00 | 0.00 | -0.05 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | - | - | - | 0.00 | - | - |
| Change in Capital Stock | 1.70+132.9% | -0.01-101.7% | 6.07+166.2% | 1.25-26.9% | 0.73-76.6% | 0.58 | 2.28 | 1.71 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.70+132.9% | -0.01-101.7% | 6.07+166.2% | 1.25-26.9% | 0.73-76.6% | 0.58 | 2.28 | 1.71 |
| Proceedsfrom Stock Options | 7.11+874.0% | 0.00-100.0% | 0.66-71.1% | 1.25-26.9% | 0.73-76.6% | 0.58 | 2.28 | 1.71 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 1.70+132.9% | -0.01-101.7% | 6.07+166.2% | 1.25-26.9% | 0.73-76.6% | 0.58 | 2.28 | 1.71 |
| Net Change in Cash | -0.42 | -1.94 | 4.02+4366.7% | -0.43 | -0.98-163.6% | -1.42 | 0.09 | -0.93 |
| Free Cash Flow | -2.12 | -1.93 | -2.05 | -1.68 | -1.71 | -1.99 | -2.19 | -2.64 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 3.26% | 0.8M | 24.9M | 390.10K |
| 2026-10-15 | 4.59% | 1.1M | 24.9M | 422.45K |
| 2026-09-30 | 3.72% | 0.9M | 24.9M | 447.93K |
| 2026-09-15 | 2.36% | 0.6M | 24.9M | 353.79K |
| 2026-08-31 | 2.59% | 0.6M | 24.9M | 353.06K |
| 2026-08-14 | 3.52% | 0.9M | 24.8M | 923.99K |
| 2026-07-31 | 2.41% | 0.6M | 24.7M | 946.75K |
| 2026-07-15 | 3.27% | 0.7M | 22.4M | 943.95K |
| 2026-06-30 | 3.96% | 0.9M | 22.4M | 895.23K |
| 2026-06-15 | 3.37% | 0.8M | 22.4M | 859.98K |
| 2026-05-29 | 7.47% | 1.7M | 22.2M | 850.52K |
| 2026-05-15 | 3.34% | 0.7M | 21.1M | 281.06K |
| 2026-04-30 | 3.40% | 0.7M | 21.0M | 249.70K |
| 2026-04-15 | 3.49% | 0.7M | 21.0M | 247.96K |
| 2026-03-31 | 3.60% | 0.8M | 21.0M | 266.74K |
| 2026-03-13 | 3.84% | 0.8M | 21.0M | 285.67K |
| 2026-02-27 | 4.59% | 1.0M | 21.0M | 297.78K |
| 2026-02-13 | 4.02% | 0.8M | 21.0M | 311.34K |
| 2026-01-30 | 3.77% | 0.8M | 21.0M | 346.67K |
| 2026-01-15 | 3.14% | 0.7M | 21.0M | 370.27K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.00 | 0.05 | 0.05 | 337.8% | 488 | 0.00 | 0.169 | -0.011 | 0.001 |
| call | 5.00 | 0.00 | 0.25 | 0.00 | 622.9% | 0.00 | 0.00 | 0.199 | -0.021 | 0.001 |
| call | 7.50 | 0.00 | 0.05 | 0.05 | 735.7% | 100 | 0.00 | 0.181 | -0.024 | 0.001 |
| put | 2.50 | 0.00 | 3.60 | 1.17 | - | 0.00 | 0.00 | -0.831 | -0.011 | 0.000 |
| put | 5.00 | 2.00 | 6.00 | 0.00 | - | 0.00 | 0.00 | -0.875 | -0.014 | 0.000 |
| put | 7.50 | 4.50 | 8.50 | 0.00 | - | 0.00 | 0.00 | -0.888 | -0.015 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-21 | 424B5 | SEC | ||
| 2026-10-08 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-11-21 | SEC |
| 2026-09-29 | 8-K | Current report | 2026-09-28 | SEC |
| 2026-09-28 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-09-03 | 424B3 | SEC | ||
| 2026-08-31 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-08-21 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-07-30 | 8-K | Current report | 2026-07-24 | SEC |
| 2026-07-27 | 424B5 | SEC | ||
| 2026-07-27 | 424B5 | SEC | ||
| 2026-07-17 | 8-K | Current report | 2026-07-17 | SEC |
| 2026-07-17 | 424B5 | SEC | ||
| 2026-07-01 | 424B3 | SEC | ||
| 2026-06-26 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-06-23 | CORRESP | SEC | ||
| 2026-06-22 | DEL AM | Separately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statement | SEC | |
| 2026-06-18 | UPLOAD | Upload Submission | SEC | |
| 2026-06-17 | DEL AM | Separately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statement | SEC | |
| 2026-06-15 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-06-15 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-06-11 | CORRESP | SEC | ||
| 2026-06-10 | UPLOAD | Upload Submission | SEC | |
| 2026-06-05 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-05-21 | 8-K | Current report | 2026-05-20 | SEC |
| 2026-05-20 | 8-K | Current report | 2026-05-15 | SEC |
| 2026-05-18 | 424B5 | SEC | ||
| 2026-05-15 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-02-25 | D | Notice of sales of securities on Form D (Regulation D) | SEC | |
| 2026-02-17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2025-12-30 | 424B3 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 4.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.90% |
| Connective Capital Management, LLC | 0.81% |
| BlackRock, Inc. | 0.69% |
| VANGUARD FIDUCIARY TRUST CO | 0.57% |
| Miller Financial Services LLC | 0.52% |
| RENAISSANCE TECHNOLOGIES LLC | 0.39% |
| Creative Planning | 0.34% |
| UBS Group AG | 0.28% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.26% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.84% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.07% |
| Fidelity Extended Market Index Fund | 0.49% |
| Ultra-Small Company Market Fund | 0.16% |
| Fidelity Series Total Market Index Fund | 0.14% |
| Fidelity Total Market Index Fund | 0.09% |
| VANGUARD BALANCED INDEX FUND | 0.09% |
OakChart. NNVC. Cached 15 minutes. Terms
Some panels did not load: insider.